SCHEMBL255337

SCHEMBL255337

CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)OC)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 6/20 0.84
PPARG P37231 4/20 0.84
AGTR2 P50052 4/20 0.84
KDM4E B2RXH2 1/20 0.84
ABCC3 O15438 1/20 0.84
ABCC4 O15439 1/20 0.84
USP2 O75604 1/20 0.84
ABCB11 O95342 1/20 0.84
ALDH1A1 P00352 1/20 0.84
CHRM2 P08172 1/20 0.84
CYP3A4 P08684 1/20 0.84
ADRA2A P08913 1/20 0.84
ADORA3 P0DMS8 1/20 0.84
CHRM1 P11229 1/20 0.84
CYP2C9 P11712 1/20 0.84
ACE P12821 1/20 0.84
ADRA2C P18825 1/20 0.84
TBXA2R P21731 1/20 0.84
GLRA1 P23415 1/20 0.84
PDE4A P27815 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3229877 0.94 PPARG (0.84) AGTR1PPARGAGTR2KDM4EABCC3
SCHEMBL12606482 0.94 AGTR1 (0.73) AGTR1PPARGAGTR2KDM4EABCC3
SCHEMBL17948609 0.93 PPARG (0.84) AGTR1PPARGAGTR2KDM4EABCC3
SCHEMBL19432748 0.92 PPARG (0.81) AGTR1PPARGAGTR2KDM4EABCC3
SCHEMBL10021554 0.92 AGTR1 (0.80) AGTR1PPARGAGTR2KDM4EABCC3
SCHEMBL170874 0.92 PPARG (0.80) AGTR1PPARGAGTR2KDM4EABCC3
SCHEMBL6080037 0.92 AGTR1 (0.75) AGTR1PPARGAGTR2KDM4EABCC3
SCHEMBL9229548 0.91 AGTR1 (0.85) AGTR1PPARGAGTR2KDM4EABCC3
Telmisartan SCHEMBL4464 0.91 AGTR1 (1.00) AGTR1PPARGAGTR2KDM4EABCC3
SCHEMBL17946015 0.91 PPARG (0.88) AGTR1PPARGAGTR2KDM4EABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211866-A1 Process for the preparation of angiotensin receptor blockers and intermediates thereof GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-09-21 US claimed
US-8293777-B2 Angiotensin II receptor antagonists MERCK SHARP & DOHME, CORP. (US) 2012-10-23 US disclosed
US-8252825-B2 Angiotensin II receptor antagonists NICOX (IT) 2012-08-28 US disclosed
WO-2012028925-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF TELMISARTAN OGENE SYSTEMS (I) PVT LTD (IN) 2012-03-08 WO disclosed
US-8106034-B2 Angiotensin II receptor antagonists MERCK SHARP & DOHME CORP. (US) 2012-01-31 US disclosed
US-8053455-B2 Angiotensin II receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-11-08 US disclosed
WO-2011102645-A2 AN IMPROVED PROCESS FOR PREPARING TELMISARTAN DONG WHA PHARM. CO., LTD. (KR) 2011-08-25 WO disclosed
US-20110201621-A1 ANGIOTENSIN II RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-08-18 US disclosed
US-7947664-B2 Angiotensin II receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed
US-7943781-B2 Process for preparing telmisartan DR. REDDY'S LABORATORIES LIMITED (IN) 2011-05-17 US disclosed
US-20100144810-A1 ANGIOTENSIN II RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. 2010-06-10 US disclosed
WO-2009006860-A2 A METHOD OF MANUFACTURING 4'-[[4-METHYL-6-(1-METHYL-1H-BENZIMIDAZOL-2-YL)-2-PROPYL-1H-BENZIMIDAZOL-1YL]METHYL]BIPHENYL-2-CARBOXYLIC ACID (TELMISARTAN) ZENTIVA A.S. (CZ) 2009-01-15 WO disclosed
EP-1805146-A4 PROCESS FOR PREPARING TELMISARTAN REDDYS LAB LTD DR (IN) 2009-01-14 EP disclosed
US-20070287840-A1 Process for Preparing Telmisartan DR. REDDY'S LABORATORIES LIMITED (IN) 2007-12-13 US disclosed
US-20070287840-A1 Process for Preparing Telmisartan DR. REDDY'S LABORATORIES LIMITED (IN) 2007-12-13 US disclosed
EP-1805146-A2 PROCESS FOR PREPARING TELMISARTAN Dr. Reddy's Laboratories Ltd. (IN) 2007-07-11 EP disclosed
WO-2006136916-A2 SUBSTANTIALLY PURE MICRONIZED PARTICLES OF TELMISARTAN AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME GLENMARK PHARMACEUTICALS LIMITED (US) 2006-12-28 WO disclosed
WO-2006136916-A2 SUBSTANTIALLY PURE MICRONIZED PARTICLES OF TELMISARTAN AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME GLENMARK PHARMACEUTICALS LIMITED (US) 2006-12-28 WO disclosed
US-20060211866-A1 Process for the preparation of angiotensin receptor blockers and intermediates thereof GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-09-21 US disclosed
WO-2006044754-A2 PROCESS FOR PREPARING TELMISARTAN DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201621-A1 ANGIOTENSIN II RECEPTOR ANTAGONISTS AGTR1, AGTR2, REN AGTR1 1/4885PPARG 1454/4885AGTR2 2/4885
US-20060211866-A1 Process for the preparation of angiotensin receptor blockers and intermediates thereof AGTR1, AGTR2, BDKRB1 AGTR1 1/4885PPARG 741/4885AGTR2 2/4885
US-20070287840-A1 Process for Preparing Telmisartan AGT, TTR, REN AGTR1 4/4885PPARG 2394/4885AGTR2 10/4885
US-20100144810-A1 ANGIOTENSIN II RECEPTOR ANTAGONISTS AGTR1, AGTR2, REN AGTR1 1/4885PPARG 882/4885AGTR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.